Navigation Links
Aragon Pharmaceuticals Announces Appointment of Faheem Hasnain as Independent Director
Date:8/28/2012

SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- Aragon Pharmaceuticals today announced the appointment of Faheem Hasnain as an independent director of the Company's board of directors.

(Logo: http://photos.prnewswire.com/prnh/20120828/SF63676LOGO)

Mr. Hasnain brings more than 20 years of experience in the pharmaceutical and biotechnology industries, with executive leadership roles at leading public companies, including Facet Biotech Corporation, PDL BioPharma, Biogen Idec, Bristol Myers-Squibb and GlaxoSmithKline.

"Faheem's expansive commercialization, leadership and public as well as private company experience will prove invaluable to Aragon as we work to advance our programs targeting hormone dependent cancers, including ARN-509, an anti-androgen for the treatment of castration-resistant prostate cancer that is progressing toward registration-enabling trials next year," said Richard A. Heyman, Ph.D., President and CEO of Aragon.

"The team at Aragon Pharmaceuticals has pioneered a very promising small molecule discovery platform for anti-hormonal agents, and I look forward to being involved in their future development efforts as they continue to advance in this promising field," said Mr. Hasnain.

Hasnain currently serves as President and CEO of Receptos, Inc. and is a previous President, Chief Executive Officer and Director of Facet Biotech Corporation, which was sold to Abbot Laboratories for over $700 million in April 2010. Prior to that, Mr. Hasnain was President, Chief Executive Officer and a Director of PDL BioPharma, Inc. Mr. Hasnain served at Biogen Idec Inc. as Executive Vice President in charge of the oncology/rheumatology strategic business unit. He also held roles with Bristol-Myers Squibb, where he was president of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations. Hasnain is Chairman of the board of Ambit Biosciences Corporation and Sente, Inc. and serves on the board of directors of Somaxon Pharmaceuticals. He received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.

About Aragon Pharmaceuticals

Aragon Pharmaceuticals is focused on the development of second generation anti-hormonal agents for hormone-driven cancers. The company's portfolio of small molecule therapeutics is based upon pioneering research identifying key molecular events that lead to drug resistance to traditional anti-hormonal therapies. This work has broad implications for the development of breakthrough medicines for prostate cancer and other hormone-dependent cancers such as breast, ovarian and endometrial cancer. Aragon Pharmaceuticals' most advanced compound, ARN-509, is an androgen receptor antagonist that is currently being evaluated in a Phase 2 trial in patients with castration-resistant prostate cancer. In addition, Aragon Pharmaceuticals has a selective estrogen receptor degrader (SERD) for hormone-sensitive and hormone-resistant estrogen receptor positive breast cancer targeted to begin clinical trials in 2012. Aragon is a private company founded in 2009 and headquartered in San Diego, California. For more information, visit www.aragonpharm.com.

 


'/>"/>
SOURCE Aragon Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Paragon Bioservices, Inc. Wins The 2012 CMO Leadership Award
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
Breaking Medicine Technology:
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
Breaking Medicine News(10 mins):